Methicillin-resistant Staphylococus aureus and vancomycin-resistant enterococci: Therapeutic realities and possibilities

Lancet

Volumn 349, Issue 9069, 1996, Pages 1901-1906

  Michel, M ^a   Gutmann, L ^a  

^a HÔPITAL BROUSSAIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; GLYCOPEPTIDE; METICILLIN; VANCOMYCIN; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; ENTEROCOCCUS; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; CROSS INFECTION; DRUG COMBINATION; DRUG EFFECT; GENETICS; MICROBIOLOGY; MULTIDRUG RESISTANCE; PENICILLIN RESISTANCE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; ENTEROCOCCUS; FLUOROQUINOLONES; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; METHICILLIN RESISTANCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 0031589377     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)11192-2     Document Type: Review

References (62)

1. 1 Wenzel RP, Nettleman MD, Jones RV, Pfaller MA. Methicillin-resistant Staphylococcus aureus: implications for the 1990s and effective control measures. Am J Med 1991; 91 (suppl 3B): 221S-26S.
2. 2 De Lencastre H, de jonge BLM, Matthews PR, Tomasz A. Molecular aspects of methicillin resistance in Staphylococcus aureus. J Antimicrob Chemother 1994; 33: 7-24.
3. 3 Bates J, Jordens JZ, Griffiths DT. Farm animals as a putative reservoir for vancomycin-resistant enterococcal infection in man. J Antimicrob Chemother 1994; 34: 507-16.
4. 4 Uttley AH, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1988; i: 57-58.
5. 5 Noble WC, Virani Z, Cree RGA. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992; 93: 195-98.
6. 6 Mainardi JL, Shlaes DM, Goering RV, Shlaes JH, Acar JF, Goldstein FW. Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus. J Infect Dis 1995; 171: 1646-60.
7. 7 Finland M. Emergence of antibiotic resistance in hospitals, 1935-1975. Rev Infect Dis 1979; 1: 4-21.
8. 8 Barber M. Methicillin-resistant staphylococci. J Clin Pathol 1961; 14: 385-93.
9. 9 Voss A, Milatovic D Wallrauch-Schwarz C, Rosdahl VT, Braveny I. Methicillin-resistant Staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis 1994; 13: 50-55.
10. 10 Brumfitt W, Hamilton-Miller J. Methicillin-resistant Staphylococcus aureus. N Engl J Med 1989; 320: 1188-96.
11. 11 Henze UU, Berger-Bächi B. Staphylococcus aureus penicillin-binding protein 4 and intrinsic β-lactam resistance. Antimicrob Agents Chemother 1995; 39: 2415-22.
12. 12 Archer GL, Niemeyer DM. Origin and evolution of DNA associated with resistance to methicillin in staphylococci. Trends Microbiol 1994; 3: 343-37.
13. 13 Berger-Bächi B. Expression of resistance to methicillin. Trends Microbiol 1994; 2: 389-92.
14. 14 Hackbarth CJ, Chambers HF. blaI and blaR1 regulate β-lactamase and PLP2A production in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1994; 38: 447-54.
15. 15 McDougall LK, Thornsberry C. The role of β-lactamase in staphylococcal resistance to penicillin-resistant penicillins and cephalosporins. J Clin Microbiol 1986; 23: 832-39.
16. 16 Tomasz A, Drugeon HB, De Lencastre HM, Jabes D, McDougal L, Bille J. New mechanism for methicillin resistance in Staphylococcus aureus: clinical isolates that lack the PLP2a gene and contain normal penicillin-binding capacity. Antimicrob Agents Chemother 1989; 33: 1869-74.
17. 17 Maple PAC, Hamilton-Miller J, Brumfitt W. World-wide antibiotic resistance in methicillin-resistant Staphylococcus aureus. Lancet 1989; i: 537-40.
18. 18 Ackerman BH, Vannier AM, Eudy EB. Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmocodynamic response. Antimicrob Agents Chemother 1992; 36: 1766-69.
19. 19 Bayer AS, Lam K. Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations. J Infect Dis 1985; 151: 157-65.
20. 20 Fantin B, Leclerq R, Duval J, Carbon C. Fusidic acid alone or in combination with vancomycin for therapy of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1993; 37: 2466-69.
21. 21 Rodriquez A, Vicente MV, Olay T. Single- and combination-antibiotic therapy for experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1987; 31: 1444-45.
22. 22 Markowitz N, Quinn EL, Saravoltz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992; 117: 390-98.
23. 23 Portier H, Tremeaux JC, Chavanet P, Gouyon JB, Deuz JM, Kazmierczak A. Treatment of severe staphylococcal infections with cefotaxime and fosfomycin in combinmation. J Antimicrob Chemother 1984; 14 (suppl B): 277-84.
24. 24 Franciolli M, Bille J, Glauser MP, Moreillon P. β-lactam resistance mechanisms of methicillin-resistant Staphylococcus aureus. J Infect Dis 1991; 163: 514-23.
25. 25 Chambers HF. In vitro and in vivo antistaphylococcal activities of L-695,256, a carbapenem with high affinity for the penicillin-binding protein PBP2a. Antimicrob Agents Chemother 1995; 39: 462-66.
26. 26 Brumfitt W, Hamilton-Miller J, Shah S. In vitro activity of RP59500, a new semi-synthetic steptogramin antibiotic against Gram positive bacteria. J Antimicrob Chemother 1992; 30 (suppl A): 29-37.
27. 27 Fantin B, Leclerq R, Ottaviani M, et al. In vivo activities and pentration of the two components of the streptogramin RP 59550 in cardiac vegetations of experimental endocarditis. Antimicrob Agents Chemother 1994; 30 (suppl A): 29-37.
28. 28 Entenza JM, Drugeon H, Glauser MP, Moreillon P. Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant Staphylococcus aureus with RP59500. Antimicrob Agents Chemother 1995; 39: 1419-24.
29. 29 Torralba MD, Frey SE, Lagging LM. Treatment of methicillin-resistant Staphylococcus aureus infection with quinupristin/dalfopristin. Clin Infect Dis 1995; 21: 460-61.
30. 30 Cagni A, Chuard C, Vaudaux PE, Schrenzel J, Len DP. Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1995; 39: 1655-60.
31. 31 Ford CW, Hamel JC, Wilson DM, et al. In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents against experimental bacterial infections. Antimicrob Agents Chemother 1996; 40: 1508-13.
32. 32 Ramsey MA, Bradley SF, Kauffman CA, Morton TM. Identification of chromosomal location of mupA gene encoding low-level mupirocin resistance in 8 staphylococcal isolates. Antimicrob Agents Chemother 1996; 40: 2820-23.
33. 33 Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med 1991; 91 (suppl 3B): 72S-75S.
34. 34 Patterson JE, Zervos MJ. High-level gentamicin resistance in Enterococcus: microbiology, genetic basis, and epidemiology. Rev Infect Dis 1990; 12: 644-52.
35. 35 Zorzi W, Zhou XY, Dardenne O, et al. Structure of the low affinity penicillin-binding protein 5 PBP5fm in wild type and highly penicillin resistant strains of Enterococcus faecium. J Bacteriol 1996; 178: 4968-57.
36. 36 Leclerq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988; 319: 1571-76.
37. 37 Centers for Disease Control and Prevention. 1989-1993. Nosocomial enterococci resistant to vancomycin. MMWR 1993; 42: 597-99.
38. 38 Witte W, Klare I. Glycopeptide-resistant Enterococcus faecium outside hospitals: a commentary. Microb Drug Resist 1995; 1: 259-63.
39. 39 Wade HH, Rolando N, Casewell MW. Serious infections caused by multiply-resistant Enterococcus faecium. Microb Drug Resist 1995; 1: 241-43.
40. 40 Shlaes DM, Rice LB. Bacterial resistance to the cyclic glycopeptides. Trends Microbiol 1994; 2: 385-88.
41. 41 Arthur M, Reynolds P, Courvalin P. Glycopeptide resistance in enterococci. Trends Microbiol 1996; 4: 401-07.
42. 42 Woodford N, Johnson AP, Morrison D, Speller DC. Current perspectives on glycopeptide resistance. Clin Microbiol Rev 1995; 8: 585-615.
43. 43 Billot-Klein D, Gutmann L, Sablé S, Guittet E, Van Heijenoort J. Modification of peptidoglycan precursors is a common feature of the low-level vancomycin-resistant VANB-type enterococcus D366 and the naturally glycopeptide-resistant species. Lactobacillus casei, Pediococcus mesenteroïdes and Enterococcus gallinarum. J Bacteriol 1994; 176: 2398-405.
44. 44 Billot-Klein D, Gutmann L, Bryant D, et al. Peptidoglycan synthesis and structure in Staphylococcus haemolyticus expressing increasing levels of resistance to glycopeptide antibiotics. J Bacteriol 1996; 178: 4696-703.
45. 45 Caron F, Lemeland JF, Hubert G, Klare I, Gutmann L. Triple combination penicillin-vancomycin-gentamicin for experimental endocarditis caused by a highly penicillin- and glycopeptide-resistant isolate of Enterococcus faecium. J Infect Dis 1993; 168: 681-86.
46. 46 Caron F, Pestel M, Kitzis MD, Lemeland JF, Humbert G, Gutmann L. Comparison of different β-lactam glycopeptide-gentamicin combinations for an experimental endocarditis caused by a highly β-lactam-resistant and highly glycopeptide-resistant isolate of Enterococcus faecium. J Infect Dis 1995; 171: 106-12.
47. 47 Gutmann L, Al-Obeid S, Billot-Klein D, Guerrier ML, Collatz E. Synergy and resistance to synergy between β-lactam antibiotics and glycopeptides against glycopeptide-resistant strains of Enterococcus faecium. Antimicrob Agents Chemother 1994; 38: 824-29.
48. 48 Nicolau DP, Marangos MN, Nightingale CH, et al. Efficacy of vancomycin and teicoplanin alone and in combination with streptomycin in experimental low-level vancomycin-resistant, VanB-type Enterococcus faecalis endocarditis. Antimicrob Agents Chemother 1996; 40: 55-60.
49. 49 Whitman MS, Pitsakis PG, Zausner A, et al. Antibiotic treatment of experimental endocarditis due to vancomycin- and ampicillin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1993; 37: 2069-73.
50. 50 Brandt CM, Rouse MS, Laue NW, Stratton CW, Wilson WR, Steckelberg JM. Effective treatment of multidrug-resistant enterococcal experimental endocarditis with combinations of cell-wall active agents. J Infect Dis 1996; 173: 909-13.
51. 51 Unal S, Flokowitsch J, Mullen DL, Preston DA, Nicas TI. In-vitro synergy and mechanism of interaction between vancomycin and ciprofloxacin against enterococal isolates. J Antimicrob Chemother 1993; 31: 711-23.
52. 52 Caron F, Pestel M, Gutmann L, Humbert G, Lemeland JF. Synergy between ceftriaxone and fosfomycin in the treatment of an experimental endocarditis due to vancomycin-susceptible (VanS) or vancomycin-resistant (VanA) Enterococcus faecium. (abstract B47). Program and abstract of the 35th International Conference on Antimicrobial Agents and Chemotherapy; San Francisco. American Society for Microbiology, 1995.
53. 53 Norris AH, Reilly JP, Edelstein PH, Brennan PJ, Schuster MG. Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections. Clin Infect Dis 1995; 20: 1137-40.
54. 54 Collins LA, Malanoski GJ, Eliopoulos GM, Wennersten CB, Ferraro MJ, Mollering RC Jr. In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother 1993; 37: 598-601.
55. 55 Ristow TA, Noskin GA, Warren JR, Peterson LR. In vitro activity of RP59500 (quinupristin/dalfopristin) and ramoplanin against vancomycin-resistant Enterococcus faecium. Microb Drug Resist 1995; 1: 335-39.
56. 56 Sahgal VS, Urban C, Mariano N, Weinbaum F, Turner J, Rahal JJ. Quinupristin/dalfopristin (RP59500) therapy for vancomycin-resistant Enterococcus faecium aortic graft infection: case report. Microb Drug Resist 1995; 1: 245-47.
57. 57 Dever LL, Smith SM, Dejesus D, et al. Treatment of vancomycin-resistant Enterococcus faecium infections with an investigational streptogramin antibiotic (quinupristin/dalfopristin): a report of fifteen cases. Microbiol Drug Resist 1996; 2: 407-13.
58. 58 Nicas TI, Mullen DL, Flokowitsch JE, et al. Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria. Antimicrob Agents Chemother 1995; 39: 2585-87.
59. 59 Vasquez J, Perri MB, Thal LA, Donadedian SA, Zervos MJ. Sparfloxacin and clinafloxacin alone or in combination with gentamicin for therapy of experimental ampicillin-resistant enterococcal endocarditis in rabbits. J Antimicrob Chemother 1993; 32: 356-58.
60. 60 Fraise AP, Brenwald N, Andrews JM, Wise R. In-vitro activity of two glycylcyclines against enterococci resistant to other agents. J Antimicrob Chemother 1995; 35: 877-81.
61. 61 Cohen MA, Yoder SL, Huband MD, Roland GE, Courtney C. In vitro activities of clinafloxacin; CI-990 (PD131112) and PD138312 versus enterococci. Antimicrob Agents Chemother 1995; 39: 2123-27.
62. 62 O'Donovan CA, Fan-Havard P, Tecson-Tumand FT, Smith SM, Eng RHK. Enteric eradication of vancomycin-resistant Enterococcus faecium with oral bacitracin. Diagn Microbiol Infect Dis 1994; 18: 105-09.